CPT code 90586 designates intravesical administration of a live vaccine product for the treatment of bladder cancer. This immunotherapeutic procedure is clinically significant as a bladder-preserving therapy option for non-muscle invasive bladder cancer and is commonly performed in outpatient surgical settings. It carries implications for payer coverage, billing practices, and facility workflows nationwide.

Key payers in the national analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how this code is used clinically, common payment and billing considerations observed across major payers, and context on where the service is typically delivered. The publication also summarizes available benchmarks and policy updates relevant to intravesical live vaccine administration, and highlights procedural coding nuances that affect claims processing.

This summary is intended to inform billing managers, revenue cycle staff, and clinical administrators about the clinical purpose of CPT code 90586, expected sites of service, and the payer landscape. Data not available in the input is noted where appropriate in detailed sections.